Strategic Partnership with Royalty Pharma Enhances Revolution Medicines’ Financial Flexibility and Growth Potential

Revolution Medicines secures $2 billion funding deal with Royalty Pharma

Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for Patients with RAS-Addicted Cancers

FDA Breakthrough: Revolutionary Pancreatic Cancer Drug Targets Critical KRAS Mutations in Late-Stage Patients

Revolution Medicines Lands Massive $2B Deal to Advance Revolutionary Cancer Treatment Program